Table 5 Toxicity summary in eligible patients–overall and by treatment phase
Overall N (%) | Induction N (%) | CNS N (%) | Intensification N (%) | Continuation N (%) | |
|---|---|---|---|---|---|
No. patients reporting | 92 | 92 | 67 | 62 | 48 |
CTC grade 3–5 toxicity | |||||
Neutrophils | 86 (93) | 82 (89) | 10 (15) | 52 (84) | 22 (46) |
Platelets | 75 (82) | 72 (78) | 1 (1) | 17 (27) | 5 (10) |
Febrile neutropenia | 30 (33) | 20 (22) | 0 (0) | 10 (16) | 3 (6) |
Infection with grade 3/4 neutropeniaa | 49 (53) | 41 (45) | 1 (1) | 11 (18) | 6 (13) |
Infection—other | 7 (8) | 2 (2) | 1 (1) | 3 (5) | 2 (4) |
Hepatica | 57 (62) | 24 (26) | 5 (7) | 33 (53) | 21 (44) |
Hyperglycemia | 41 (45) | 36 (39) | 1 (1) | 12 (19) | 5 (10) |
Stomatitis | 10 (11) | 4 (4) | 1 (1) | 5 (8) | 0 (0) |
CNS hemorrhagea | 1 (1) | 1 (1) | 0 (0) | 1 (2) | 0 (0) |
Seizure | 4 (4) | 1 (1) | 0 (0) | 3 (5) | 1 (2) |
Asparaginase-related toxicity | |||||
Pancreatitisa | 10 (11) | 1 (1) | 0 (0) | 8 (13) | 2 (4) |
Allergy/rash | 5 (5) | 1 (1) | 0 (0) | 4 (6) | 0 (0) |
Thrombosis/embolism | 16 (17) | 1 (1) | 0 (0) | 14 (23) | 2 (4) |
Bone fracture | 7 (8) | 0 (0) | 0 (0) | 3 (5) | 5 (10) |
Avascular necrosis | 5 (5) | 0 (0) | 0 (0) | 2 (3) | 4 (8) |
